REQUEST A DEMO
Total
USD $0.00
Search more companies

Ngenebio Co., Ltd. (South Korea)

Main Activities: Pharmaceutical and Medicine Manufacturing | In-Vitro Diagnostic Substance Manufacturing | Software Publishers | Medical Laboratories
Full name: Ngenebio Co., Ltd. Profile Updated: June 12, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English Download a sample report

Ngenebio Co., Ltd. is an enterprise in South Korea, with the main office in Seoul. The company operates in the Pharmaceutical and Medicine Manufacturing sector. Ngenebio Co., Ltd. was incorporated on October 30, 2015. The total number of employees is currently 101 - 500 (2025). From the latest financial highlights, Ngenebio Co., Ltd. reported a net sales revenue increase of 273.22% in 2025. Its’ total assets recorded a growth of 119.54%. The net profit margin of Ngenebio Co., Ltd. increased by 213.17% in 2025.

Headquarters
303-307, 314Ho, 288, Digital-Ro, Guro-Gu
Seoul; Seoul;

Contact Details: Purchase the Ngenebio Co., Ltd. report to view the information.

Website: http://ngenebio.com

Basic Information
Total Employees:
Purchase the Ngenebio Co., Ltd. report to view the information.
Outstanding Shares:
Purchase the Ngenebio Co., Ltd. report to view the information.
Registered Capital:
Purchase the Ngenebio Co., Ltd. report to view the information.
Financial Auditors:
Purchase the Ngenebio Co., Ltd. report to view the information.
Incorporation Date:
October 30, 2015
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
(주)진메디카
Company Performance
Financial values in the chart are available after Ngenebio Co., Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
273.22%▲
Total Operating Revenue
401.34%▲
Operating Profit
86.08%▲
EBITDA
N/A
Net Profit/Loss for the Period
51.53%▲
Total Assets
119.54%▲
Total Equity
27.58%▲
Operating Profit Margin
275.14%▲
Net Profit Margin
213.17%▲
Return on Equity (ROE)
48.82%▲
Debt / Equity
96.24%▲
Quick Ratio
-0.29%▼
Cash Ratio
-0.31%▼

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?